TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation.


Journal

Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562

Informations de publication

Date de publication:
03 2019
Historique:
received: 16 01 2018
accepted: 05 07 2018
revised: 03 07 2018
pubmed: 8 11 2018
medline: 10 5 2019
entrez: 8 11 2018
Statut: ppublish

Résumé

Malignant mesothelioma (MM) constitutes a very aggressive tumor that is caused by asbestos exposure after long latency. The NF2 tumor suppressor gene is mutated in 40-50% of MM; moreover, one of its downstream signaling cascades, the Hippo signaling pathway, is also frequently inactivated in MM cells. Although the YAP transcriptional coactivator, which is regulated by the Hippo pathway, can function as a pro-oncogenic protein, the role of TAZ, a paralog of YAP, in MM cells has not yet been clarified. Here, we show that TAZ is expressed and underphosphorylated (activated) in the majority of MM cells compared to immortalized mesothelial cells. ShRNA-mediated TAZ knockdown highly suppressed cell proliferation, anchorage-independent growth, cell motility, and invasion in MM cells harboring activated TAZ. Conversely, transduction of an activated form of TAZ in immortalized mesothelial cells enhanced these in vitro phenotypes and conferred tumorigenicity in vivo. Microarray analysis determined that activated TAZ most significantly enhanced the transcription of genes related to "cytokine-cytokine receptor interaction." Among selected cytokines, we found that IL-1 signaling activation plays a major role in proliferation in TAZ-activated MM cells. Both IL1B knockdown and an IL-1 receptor antagonist significantly suppressed malignant phenotypes of immortalized mesothelial cells and MM cells with activated TAZ. Overall, these results indicate an oncogenic role for TAZ in MMs via transcriptional induction of distinct pro-oncogenic genes including cytokines. Among these, IL-1 signaling appears as one of the most important cascades, thus potentially serving as a target pathway in MM cells harboring Hippo pathway inactivation.

Identifiants

pubmed: 30401981
doi: 10.1038/s41388-018-0417-7
pii: 10.1038/s41388-018-0417-7
doi:

Substances chimiques

Cytokines 0
Intracellular Signaling Peptides and Proteins 0
Trans-Activators 0
Transcription Factors 0
Transcriptional Coactivator with PDZ-Binding Motif Proteins 0
WWTR1 protein, human 0
Protein Serine-Threonine Kinases EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1966-1978

Subventions

Organisme : Japan Society for the Promotion of Science (JSPS)
ID : 25090053
Pays : International
Organisme : Japan Society for the Promotion of Science (JSPS)
ID : 16H04706
Pays : International
Organisme : Japan Society for the Promotion of Science (JSPS)
ID : 17K19628
Pays : International

Références

Nat Rev Cancer. 2017 Jul 25;17(8):475-488
pubmed: 28740119
N Engl J Med. 2005 Oct 13;353(15):1591-603
pubmed: 16221782
J Exp Med. 2012 Mar 12;209(3):479-94
pubmed: 22329991
Int J Cancer. 2006 Sep 15;119(6):1303-11
pubmed: 16642474
Nat Rev Cancer. 2015 Feb;15(2):73-79
pubmed: 25592648
Oncogene. 2012 Dec 6;31(49):5117-22
pubmed: 22286761
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Cancer Cell. 2016 Jun 13;29(6):783-803
pubmed: 27300434
Curr Treat Options Oncol. 2017 Aug;18(8):48
pubmed: 28681207
Cancer Res. 2011 Feb 1;71(3):873-83
pubmed: 21245096
Mol Cell Biol. 2007 Sep;27(18):6383-95
pubmed: 17636028
Cancer Res. 1995 Mar 15;55(6):1227-31
pubmed: 7882313
Carcinogenesis. 2008 Nov;29(11):2139-46
pubmed: 18725387
Biochem J. 2005 May 15;388(Pt 1):217-25
pubmed: 15628970
Ann Glob Health. 2014 Jul-Aug;80(4):257-62
pubmed: 25459326
J Biol Chem. 2009 May 22;284(21):14347-58
pubmed: 19324876
Science. 2005 Aug 12;309(5737):1074-8
pubmed: 16099986
Transl Lung Cancer Res. 2014 Apr;3(2):75-83
pubmed: 25806284
Mol Cell Biol. 2014 May;34(9):1607-21
pubmed: 24550007
Clin Cancer Res. 2017 Jun 15;23(12):3191-3202
pubmed: 28003305
Wound Repair Regen. 2006 Mar-Apr;14(2):187-94
pubmed: 16630108
Cell. 2011 Nov 11;147(4):759-72
pubmed: 22078877
J Clin Oncol. 2017 Oct 10;35(29):3354-3362
pubmed: 28817374
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D354-7
pubmed: 16381885
Nat Cell Biol. 2008 Jul;10(7):837-48
pubmed: 18568018
Eur Respir Rev. 2016 Dec;25(142):472-486
pubmed: 27903668
J Biol Chem. 2012 Jul 27;287(31):26245-53
pubmed: 22692215
Nat Genet. 2016 Apr;48(4):407-16
pubmed: 26928227
Cancer Res. 2008 Apr 15;68(8):2592-8
pubmed: 18413727
Oncogene. 2015 Jan 2;34(1):73-83
pubmed: 24336325
Trends Cell Biol. 2015 Sep;25(9):499-513
pubmed: 26045258
Carcinogenesis. 2013 Jul;34(7):1413-9
pubmed: 23677068
Cell. 2015 Nov 5;163(4):811-28
pubmed: 26544935
Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10854-8
pubmed: 7479897
Genes Dev. 2011 Dec 15;25(24):2594-609
pubmed: 22190458
Adv Exp Med Biol. 2014;818:127-53
pubmed: 25001534
Cancer Prev Res (Phila). 2016 May;9(5):406-414
pubmed: 26935421
Int J Oncol. 2004 Jul;25(1):173-8
pubmed: 15202003
Nat Rev Cancer. 2013 Apr;13(4):246-57
pubmed: 23467301
Carcinogenesis. 2016 Nov 1;37(11):1098-1109
pubmed: 27559111
Cytokine Growth Factor Rev. 2012 Dec;23(6):323-31
pubmed: 22981288

Auteurs

Akihiro Matsushita (A)

Division of Cancer Biology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, Japan.
Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, 65, Tsurumai-cho, Showa-ku, Nagoya, Aichi, Japan.

Tatsuhiro Sato (T)

Division of Cancer Biology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, Japan.

Satomi Mukai (S)

Division of Cancer Biology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, Japan.

Teruaki Fujishita (T)

Division of Pathophysiology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, Japan.

Emi Mishiro-Sato (E)

Division of Pathophysiology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, Japan.

Maho Okuda (M)

Division of Cancer Biology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, Japan.

Masahiro Aoki (M)

Division of Pathophysiology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, Japan.
Field of Cancer Pathobiology and Informatics, Nagoya University Graduate School of Medicine, 65, Tsurumai-cho, Showa-ku, Nagoya, Aichi, Japan.

Yoshinori Hasegawa (Y)

Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, 65, Tsurumai-cho, Showa-ku, Nagoya, Aichi, Japan.

Yoshitaka Sekido (Y)

Division of Cancer Biology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, Japan. ysekido@aichi-cc.jp.
Field of Cancer Pathobiology and Informatics, Nagoya University Graduate School of Medicine, 65, Tsurumai-cho, Showa-ku, Nagoya, Aichi, Japan. ysekido@aichi-cc.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH